Estimating Treatment Costs for Moderate and Severe Psoriasis With Comorbidities

Background. Psoriasis is the most common immune-mediated disease. Moreover, psoriasis affects not only the skin, but also a number of vital body systems. Immune deregulation is associated with an increased risk of comorbidities. The presence of concomitant diseases increases the severity and duration of treatment. This article discusses the economic component of the psoriasis treatment costs associated with type 2 diabetes mellitus. Purpose. To conduct a study comparing the costs associated with treating patients with different forms of psoriasis based on the provisions of the National Benefit Program. Materials and Methods. A single-center retrospective cohort study was conducted at the Novosibirsk Regional Clinical Dermatovenerological Dispensary in 2021–2022. To estimate the costs associated with the treatment of various clinical psoriasis forms , the study examined 210 medical records of hospitalized patients (f. 003/u). Results. The study showed that in patients with moderate and severe psoriasis, the prevalence of concomitant diseases is significantly higher; they have greater use of health care resources, including use of medications and medical services; and higher healthcare costs compared to patients without psoriasis. Conclusion. Patients with psoriasis and type 2 diabetes experienced an increase in treatment costs of 28.1% for moderate psoriasis and 9.9% for severe psoriasis. The presence of comorbid pathologies in psoriasis significantly aggravates the patient’s condition and increases the cost of treating the patient.